← Back
NeuroTrials.ai
Neurology Clinical Trial Database

FUS ET

A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor

Year of Publication: 2016

Authors: Elias WJ, Lipsman N, Ondo WG, ..., Shah BB

Journal: New England Journal of Medicine

Citation: N Engl J Med 2016;375:730-9


Clinical Question

Does MRI-guided focused ultrasound thalamotomy reduce hand tremor in patients with medication-refractory essential tremor compared to a sham procedure?

Bottom Line

MRI-guided focused ultrasound thalamotomy significantly reduced hand tremor by 47% at 3 months compared to sham procedure in patients with medication-refractory essential tremor, with sustained benefit at 12 months (40% improvement). The procedure also improved disability and quality of life but was associated with sensory disturbances (38%) and gait disturbances (36%), most of which resolved by 12 months.

Major Points

  • First randomized, sham-controlled trial of MRI-guided focused ultrasound thalamotomy for essential tremor
  • Hand tremor scores improved by 8.3 points more in thalamotomy group compared to sham at 3 months (P<0.001)
  • Benefits sustained at 12 months with 40% improvement from baseline in hand tremor
  • Significant improvements in disability (62% reduction) and quality of life (46% improvement) compared to sham
  • Unilateral procedure targeting the VIM thalamus with real-time MRI guidance and thermometry
  • Common adverse events: paresthesias/numbness (38%), gait disturbance (36%)
  • At 12 months, persistent paresthesias in 14% and gait disturbance in 9%
  • Non-invasive transcranial procedure requiring no incision or craniotomy
  • Mean of 18.5 sonications delivered with peak temperatures of 55.6°C for ablation

Design

Study Type: Randomized, double-blind, sham-controlled trial

Randomization: 1

Blinding: Double-blind (patients and assessors blinded; Tremor Research Group reviewed videotaped assessments)

Enrollment Period: August 2013 to September 2014

Follow-up Duration: 12 months

Centers: 8

Countries: United States, Canada, South Korea, Japan

Sample Size: 76

Analysis: Modified intention-to-treat; hierarchical testing design for multiple comparisons


Inclusion Criteria

  • Essential tremor diagnosed by movement disorder neurologist
  • Postural or intention tremor of hand that was moderate to severe (CRST score ≥2)
  • Disabling tremor (CRST disability subsection score ≥2 on any of 8 items)
  • Medication-refractory: failed at least 2 trials including at least one first-line agent (propranolol or primidone)
  • Stable medication doses for 30 days prior to randomization
  • Skull density ratio ≥0.45 on screening CT scan

Exclusion Criteria

  • Neurodegenerative condition
  • Unstable cardiac disease
  • Coagulopathy
  • Severe depression (PHQ-9 score ≥20)
  • Cognitive impairment (MMSE score <24)
  • Previous brain procedure (TMS, DBS, stereotactic lesioning, ECT)

Arms

FieldControlFocused Ultrasound Thalamotomy
InterventionIdentical procedure but acoustic power disengaged so no energy delivered to brainUnilateral MRI-guided focused ultrasound thalamotomy targeting VIM thalamus. Energy titrated to 55-60°C for tissue ablation. Mean 18.5±5.2 sonications.
DurationSingle procedureSingle procedure

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Change from baseline to 3 months in hand tremor score (CRST Parts A and B; 0-32 scale)Primary16.0 at baseline to 15.8 at 3 months (0.1% change)18.1 at baseline to 9.6 at 3 months (47% improvement)46.90%<0.001
Disability score (CRST Part C) at 3 monthsSecondary16.0 to 15.6 (3% reduction)16.5 to 6.2 (62% reduction)<0.001
Quality of life (QUEST score) at 3 monthsSecondary42.8 to 41.4 (3% reduction)42.6 to 23.1 (46% reduction)<0.001
Hand tremor score at 12 months (durability)SecondaryN/A (crossover at 3 months)18.1 to 10.9 (40% improvement)<0.001
Total tremor score at 3 monthsSecondary44.1 to 43.1 (2% change)50.1 to 29.6 (41% improvement)<0.001
Paresthesia or numbnessAdverse1 (5%)21 (38%) total; 8 (14%) at 12 months
Gait disturbanceAdverse1 (5%)20 (36%) total; 5 (9%) at 12 months
AtaxiaAdverse011 (20%) total; 2 (4%) at 12 months
Intraprocedural head discomfortAdverse017 (30%)
Dense permanent hypesthesia (SAE)Adverse01 patient (thumb and index finger)

Subgroup Analysis

Open-label extension cohort (19 sham crossover + 2 incomplete): Hand tremor improved 55% at 3 months and 52% at 6 months (P<0.001).


Criticisms

  • All procedures performed unilaterally - no reduction in ipsilateral tremor or axial tremors (head, neck, voice)
  • Some patients may be unable to undergo MRI studies
  • Transcranial delivery was difficult in 5 patients due to cranial characteristics
  • No comparison group undergoing DBS
  • Blinding partially compromised - 95% of active treatment and 80% of sham correctly guessed assignment
  • Benefits and risks may differ from routine practice in diverse clinical settings

Funding

InSightec, Focused Ultrasound Foundation, BIRD Foundation

Based on: FUS ET (New England Journal of Medicine, 2016)

Authors: Elias WJ, Lipsman N, Ondo WG, ..., Shah BB

Citation: N Engl J Med 2016;375:730-9

Content summarized and formatted by NeuroTrials.ai.